跳至主要内容
临床试验/EUCTR2011-002202-70-DE
EUCTR2011-002202-70-DE进行中(未招募)不适用

A prospective, non-randomized, mono-center, cohort study to evaluate the effects of 0.5mg intraocular Ranibizumab (Lucentis) injections on retinal function in patients with diabetic macular edema (DME) during twelve months - Ranibizumab short- and long-term effects on retinal function in wAMD

niversitätsklinikum Schleswig-Holstein (UK-SH)0 个研究点开始时间: 2011年6月21日最近更新:
适应症
相关药物

试验速览

阶段
不适用
状态
进行中(未招募)
发起方

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional clinical trial of medicinal product

入排标准

性别
All

入选标准

  • Diabetic macular edema with center involvement in at least one eye
  • Patients with a central retinal thickness (CRT) > 250 µm
  • Patients with a BCVA of 78-24 EDTRS letters
  • Decrease in vision is due to DME and not due to other causes, in the opinion of the investigator
  • Type 1 or type 2 diabetes mellitus diagnosed 2 years prior to screening
  • Are the trial subjects under 18? no
  • Number of subjects for this age range:
  • F.1.2 Adults (18-64 years) yes
  • F.1.2.1 Number of subjects for this age range
  • F.1.3 Elderly (>=65 years) yes
  • F.1.3.1 Number of subjects for this age range

排除标准

  • 1. history or evidence of severe cardiac disease (e.g., NYHA functional class III or IV)
  • 2. clinical or medical history uncontrolled hypertension or diabetes
  • 3. of unstable angina, acute coronary syndrome, myocardial infarction or revascularization with 6 months
  • 4. ventricular tachyarrythmias requiring ongoing treatment
  • 5. History or evidence clinically significant peripheral vascular disease, such as intermittent claudication or prior amputation
  • 6. Clinically significant impaired renal or hepatic function
  • 7. Stroke within 12 month before trial entry.
  • 8. Pregnancy
  • 9. Known serious allergies to the fluorescein dye use in angiography
  • 10. Known contraindications to the components of Lucentis® formulation.Current use of or likely need for systemic medications known to be toxic to the lens, retina or optic nerve, including Deferoxamine, Chloroquine/ hydroxychloroquine (Plaquenil), Tamoxifen, Phenothiazines and Ethambutol
  • 11. Known hypersensitivity to ranibizumab or any component of the ranibizumab formulation

研究者

发起方
niversitätsklinikum Schleswig-Holstein (UK-SH)

相似试验